Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | HPGD | P15428 | 6/20 | 1.00 |
| ▸ | CA12 | O43570 | 3/20 | 1.00 |
| ▸ | CA1 | P00915 | 3/20 | 1.00 |
| ▸ | CA2 | P00918 | 3/20 | 1.00 |
| ▸ | CA7 | P43166 | 3/20 | 1.00 |
| ▸ | CA9 | Q16790 | 3/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | HMGB1 | P09429 | 1/20 | 1.00 |
| ▸ | CA4 | P22748 | 1/20 | 1.00 |
| ▸ | CA6 | P23280 | 1/20 | 1.00 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | G6PD | P11413 | 1/20 | 0.60 |
| ▸ | CASP7 | P55210 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylic Acid SCHEMBL17156443 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDCA12CA1 | |
| Salicylic Acid SCHEMBL8433746 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDCA12CA1 | |
| Salicylic Acid SCHEMBL29606432 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDCA12CA1 | |
| Salicylic Acid SCHEMBL1509155 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDCA12CA1 | |
| Salicylic Acid SCHEMBL1967 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDCA12CA1 | |
| Salicylic Acid SCHEMBL29362663 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDCA12CA1 | |
| Salicylic Acid SCHEMBL9982 | 0.97 | ALDH1A1 (0.95) | ALDH1A1KDM4EHPGDCA12CA1 | |
| Salicylic Acid SCHEMBL299754 | 0.97 | ALDH1A1 (0.95) | ALDH1A1KDM4EHPGDCA12CA1 | |
| Salicylic Acid SCHEMBL546853 | 0.97 | ALDH1A1 (0.95) | ALDH1A1KDM4EHPGDCA12CA1 | |
| Salicylic Acid SCHEMBL12477692 | 0.97 | ALDH1A1 (0.95) | ALDH1A1KDM4EHPGDCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731628-A1 | CRYSTALLINE SALTS OF LINSITINIB FOR TREATING THYROID EYE DISEASE | Sling Therapeutics, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260014120-A1 | COMPOSITIONS AND METHODS FOR TOPICAL DELIVERY OF SALTS OF CARNOSINE AND CARNITINE | NeuviDerm LLC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250387415-A1 | COMPOSITIONS OF COPPER COMPLEXES | University of Lancashire (GB) | 2025-12-25 | — | — | US | disclosed |
| EP-4630007-A1 | SIALYLATED SACCHARIDE FOR USE IN THE PREVENTION OR TREATMENT OF AN INFLAMMATORY DISEASE AND/OR AUTOIMMUNE DISEASE | Inbiose N.V. (BE) | 2025-10-15 | — | — | EP | disclosed |
| US-12383569-B2 | Immunomodulatory oligosaccharides for the treatment of pain | INTRINSIC MEDICINE, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4583842-A1 | COMPOSITIONS OF COPPER COMPLEXES | University of Lancashire (GB) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025093572-A1 | SOLID DISPERSION COMPOSITIONS AND USES THEREOF | TRx Biosciences Limited (GB) | 2025-05-08 | — | — | WO | disclosed |
| CN-119874561-A | Charged ion channel blockers and methods of use thereof | 诺西恩医疗公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-113950471-B | Charged ion channel blockers and methods of use thereof | 诺西恩医疗公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-119233821-A | Combination therapy of PI3K inhibitors with PD-1 inhibitors | 梅制药公司 | 2024-12-31 | — | — | CN | disclosed |
| US-20230149433-A1 | IMMUNOMODULATORY OLIGOSACCHARIDES | UNIV CALIFORNIA (US) | 2023-05-18 | — | — | US | disclosed |
| CN-115279731-A | Charged ion channel blockers and methods of use thereof | 诺西恩医疗公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20220249445-A1 | ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR TREATING BLEPHARITIS | BIOPHARMA CREDIT PLC (GB) | 2022-08-11 | — | — | US | disclosed |
| US-20220193099-A1 | IMMUNOMODULATORY OLIGOSACCHARIDES FOR THE TREATMENT OF PAIN | TARGET CAPITAL 4 LLC | 2022-06-23 | — | — | US | disclosed |
| EP-3986377-A1 | ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR TREATING BLEPHARITIS | Tarsus Pharmaceuticals, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-114269324-A | Isoxazoline anthelmintic formulations and methods for treating blepharitis | 塔苏斯制药有限公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-114269951-A | Diagnostic method for aesthetic deterioration of skin | 欧莱雅 | 2022-04-01 | — | — | CN | disclosed |
| CN-114096227-A | Cosmetic compositions comprising 5-benzylaminosalicylic acid derivatives and methods of topical use thereof | 吉恩特药业株式会社 | 2022-02-25 | — | — | CN | disclosed |
| EP-3952882-A1 | IMMUNOMODULATORY OLIGOSACCHARIDES FOR THE TREATMENT OF PAIN | Intrinsic Medicine, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| US-20220024851-A1 | CRYSTALLINE FORMS OF MULTICYCLIC COMPOUNDS AND USES THEREOF | CONVELO THERAPEUTICS INC (US) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024851-A1 | CRYSTALLINE FORMS OF MULTICYCLIC COMPOUNDS AND USES THEREOF | PMP22, MAG, SSB | ALDH1A1 4134/4885KDM4E 563/4885HPGD 1724/4885 |
| US-20220193099-A1 | IMMUNOMODULATORY OLIGOSACCHARIDES FOR THE TREATMENT OF PAIN | FUT6, CSGALNACT1, FUT5 | ALDH1A1 3189/4885KDM4E 4321/4885HPGD 1751/4885 |
| US-20230149433-A1 | IMMUNOMODULATORY OLIGOSACCHARIDES | CD47, ICOS, CD74 | ALDH1A1 3851/4885KDM4E 3546/4885HPGD 2405/4885 |
| US-12383569-B2 | Immunomodulatory oligosaccharides for the treatment of pain | FUT6, CSGALNACT1, FUT5 | ALDH1A1 3189/4885KDM4E 4321/4885HPGD 1751/4885 |
| US-20250387415-A1 | COMPOSITIONS OF COPPER COMPLEXES | LIPC, NPC1L1, LIPA | ALDH1A1 668/4885KDM4E 3722/4885HPGD 2326/4885 |
| US-20260014120-A1 | COMPOSITIONS AND METHODS FOR TOPICAL DELIVERY OF SALTS OF CARNOSINE AND CARNITINE | CRAT, CCR10, SLC25A20 | ALDH1A1 1076/4885KDM4E 3554/4885HPGD 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.